Is Post Malone on Ozempic? What He's Actually Said

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• Post Malone has denied Ozempic use in multiple interviews
• He has attributed his roughly 60-pound weight loss to cutting soda (particularly Coca-Cola) and broader dietary changes, framed as a response to becoming a father
• The pattern he describes (dietary cutback, lifestyle motivation, no mention of appetite-suppression effects) is more consistent with behavioral change than with GLP-1 use
• This article treats his denial as the public record while acknowledging the general limits of relying on celebrity disclosure
• For readers wondering whether to take a denial seriously, the base-rate argument tilts toward yes, with caveats noted

Direct answer

No. Post Malone has publicly denied Ozempic use in multiple interviews. He has attributed his approximately 60-pound weight loss to cutting Coca-Cola and other dietary changes that he describes as motivated by his daughter and by wanting to be healthier long-term. His stated pattern fits behavioral change more closely than it fits GLP-1 pharmacotherapy, and no contradicting evidence has emerged in the public record.

Table of contents

1. What Post Malone has actually said
2. The Coca-Cola story: math and plausibility
3. The fatherhood framing
4. How his described pattern compares with a typical GLP-1 trajectory
5. Why he might be telling the truth: the base-rate argument
6. Why some skepticism is reasonable
7. What "cut soda and changed my diet" can and cannot do
8. The decision framework: is dietary change alone enough for you?
9. When GLP-1 therapy makes medical sense vs when it does not
10. FAQ
11. Sources

What Post Malone has actually said

Austin Post (Post Malone) has addressed weight loss across multiple interviews tied to his Austin album cycle and subsequent press runs. Across those appearances, his statements have been consistent on three points:

• He has lost approximately 60 pounds
• He attributes the change primarily to cutting Coca-Cola and adjusting his diet
• He frames the motivation as wanting to be healthier for his daughter and his work

When the Ozempic question has come up, he has denied it directly. He has emphasized eating habits, soda cessation, and being more active as the relevant factors. He has discussed the change in matter-of-fact terms rather than treating it as a transformation story to sell.

The denial has been stable across appearances. Where celebrities who later confirmed GLP-1 use (Oprah Winfrey, Tracy Morgan, Chelsea Handler) typically issued vague non-denials before confirming, Post Malone's statements have been direct denials with a specific alternative explanation attached.

The Coca-Cola story: math and plausibility

The story Post Malone has told publicly leans heavily on cutting soda. Whether that is plausible as a primary driver depends on baseline consumption.

The math assumes a roughly 3,500-calorie deficit per pound and no compensatory eating. In practice, people often replace some of the calories with other foods, so real-world losses tend to be lower than the math suggests. The general point holds: eliminating heavy soda consumption can plausibly account for substantial weight change over a year.

Post Malone has not disclosed his prior daily intake, but reporting and earlier interviews have suggested heavy soda consumption as a known feature of his lifestyle. If he was consuming in the 4 to 8 cans-per-day range, the math supports his stated outcome without requiring any pharmacological explanation.

None of this proves he is not on a GLP-1 medication. It does show that the explanation he offers is internally consistent.

The fatherhood framing

Post Malone has tied his motivation explicitly to his daughter. The framing matters in two ways.

First, it is the kind of motivation that drives durable behavioral change. People who change behavior in response to a specific external responsibility (a child, a health diagnosis, a partner's request) tend to sustain that change longer than people changing for general or aesthetic reasons. The motivational science on this is well-established.

Second, it provides a coherent narrative arc that fits a non-medication trajectory. The story is "I became a father, I wanted to be around longer, so I made changes." That story does not require GLP-1 medication to be the engine.

A skeptical reader can argue that a GLP-1 user could also adopt the same narrative as cover. That is true, but it weakens the medication hypothesis rather than strengthens it. If both stories fit the medication hypothesis equally well, then the public statements provide no specific evidence for use beyond appearance.

How his described pattern compares with a typical GLP-1 trajectory

The pattern is not a perfect filter; many GLP-1 users present without any of the typical markers being visible to outsiders. But the absence of these markers, combined with the specific alternative explanation he has provided, leans the inference toward his stated account.

Why he might be telling the truth: the base-rate argument

The base-rate framing is the strongest argument for accepting celebrity denials by default.

Consider a thought experiment. Of all celebrities who have lost visible weight since 2021 and have addressed Ozempic rumors publicly, what fraction were actually using GLP-1 medications?

The confirmed cases (Oprah Winfrey, Serena Williams, Chelsea Handler, Tracy Morgan, Amy Schumer, Whoopi Goldberg, Sharon Osbourne, Meghan Trainor, Lainey Wilson, Christina Aguilera, and others) are a meaningful set, but they are not the majority of celebrities who have lost weight in that window. Many celebrities have publicly attributed their weight loss to lifestyle change and stuck with that explanation across years without contradicting evidence.

If we assume, conservatively, that 30 to 40 percent of denying celebrities are actually using GLP-1 medications, then any individual denial is more likely to be true than false. Blanket skepticism produces a higher false-positive rate than measured trust.

This does not mean every denial is true. It means the prior should favor the denial unless specific evidence contradicts it. Post Malone's denial has not been contradicted by emergent evidence in the years since he issued it.

Why some skepticism is reasonable

The strongest counter-arguments to taking a celebrity denial at face value:

Argument 1: Brand incentives. Public figures with brand relationships may face pressure to attribute changes to discipline rather than medication. Post Malone has commercial relationships (his Maverick wine label, his Bud Light partnership, various tour and merchandise economics) that could be affected by which narrative he tells.

Argument 2: The "natural" preference. Audiences often prefer the narrative of behavioral effort to the narrative of pharmacological assistance. Sustaining the preferred narrative serves commercial interests even when the underlying truth is different.

Argument 3: Historical pattern. Cosmetic procedures (Botox, fillers, plastic surgery) were routinely denied until cultural norms shifted. GLP-1 use may follow the same arc, with denials becoming progressively less reliable over time.

Argument 4: Plausible deniability. "I cut soda and changed my diet" is a story that does not preclude additional use of medication. The narrative he tells could be true and also incomplete.

These arguments are not specific to Post Malone. They apply to any celebrity denial. The reasonable conclusion is that absolute confidence in any denial is unwarranted, while default skepticism is also unjustified. A measured prior toward truth, updated by evidence as it emerges, is the most defensible position.

What "cut soda and changed my diet" can and cannot do

For readers wondering whether a similar approach could work for them, here is the realistic picture:

What dietary change alone can do:

• Produce sustained weight loss in the 5 to 15 percent range for many people who reach a daily caloric deficit they can maintain
• Improve metabolic markers (fasting glucose, lipids, blood pressure) often more meaningfully than weight loss alone would suggest
• Provide a foundation that other interventions, if needed later, can build on
• Avoid medication side effects and supply concerns

What dietary change alone is less likely to do:

• Reach the 15 to 22 percent loss range typical of GLP-1 trials in patients who would not have lost similar amounts behaviorally
• Override metabolic adaptation in patients with significant insulin resistance
• Achieve and sustain results without significant time spent on planning, food prep, and behavior tracking
• Work without the specific motivational structure that supports sustained behavior change

Post Malone's outcome (60 pounds, paced over a clear life-change moment) falls within what dietary change alone can plausibly produce. The fact that it can be produced behaviorally does not establish that he produced it that way, but it removes one argument against his denial.

The decision framework: is dietary change alone enough for you?

If you are considering whether to try behavioral change before pursuing GLP-1 medication, the framework looks like this:

Question 1: Have you sustained behavior change before? If yes, you may have the underlying capacity to do it again. If you have repeatedly tried and reverted, the pattern is informative about how much value you might get from pharmacological support.

Question 2: What is your starting point? Higher starting BMI generally produces more dramatic dietary results in early phases, but the metabolic adaptation kicks in faster too. Lower BMI patients often see slower behavioral results and may benefit from earlier consideration of medication.

Question 3: Are there obvious behavioral targets? Post Malone's case involved a clear dietary excess (heavy soda consumption) that, once eliminated, produced visible change. If you have an equivalent excess, that becomes a starting point. If your diet is already moderate, behavioral change may produce smaller results.

Question 4: What are your comorbidities? Hypertension, dyslipidemia, type 2 diabetes, and sleep apnea respond to weight loss regardless of method, but the urgency of treatment may push you toward GLP-1 medication earlier in the decision tree.

Question 5: What does your clinician recommend? The decision is not yours alone. A clinician will weigh BMI, comorbidities, prior weight history, and medication risk factors before recommending pharmacotherapy. Their input is the most important variable.

When GLP-1 therapy makes medical sense vs when it does not

GLP-1 therapy is clinically appropriate when:

• BMI is 30 or higher, or BMI is 27 with a qualifying comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea)
• Behavioral interventions have been tried and have not produced clinically meaningful results
• Contraindications (active pancreatitis, gastroparesis, personal or family history of medullary thyroid carcinoma or MEN2, current pregnancy) are not present
• The patient and clinician have discussed expected outcomes, side effects, and maintenance planning

GLP-1 therapy is not appropriate when:

• BMI is below 27 without qualifying comorbidities
• The goal is appearance-driven rather than health-driven, and behavioral approaches have not been tried
• Contraindications are present
• The patient is unable or unwilling to commit to maintenance planning after the initial loss

For someone in Post Malone's general profile (a public figure with a documented history of heavy soda consumption, motivated by a specific life event, achieving a 60-pound loss across roughly a year), the medical case for GLP-1 therapy would have depended on his starting BMI and any comorbidities. Without that information, we cannot say whether medication would have been clinically appropriate. We can say his stated outcome is achievable without it.

Compounded medication note for this topic

For Is Post Malone on Ozempic? What He's Actually Said, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.

The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.

FAQ

Is Post Malone on Ozempic? Post Malone has denied Ozempic use in multiple interviews. He has attributed his weight loss, reported by him as roughly 60 pounds, primarily to cutting soda (particularly Coca-Cola) and broader dietary changes.

How much weight did Post Malone lose? Post Malone has stated in interviews that he lost approximately 60 pounds. He has not disclosed a specific starting or ending weight, but the figure has been consistent across his statements.

What did Post Malone say about quitting Coca-Cola? He has discussed quitting soda as a meaningful turning point. In interviews, he framed it as one of the more impactful dietary changes for his weight, his energy, and his general health.

Can you really lose 60 pounds from cutting soda? If a person was consuming many cans of full-sugar soda per day, cutting it could plausibly account for several hundred calories saved per day. Over months, that caloric deficit could produce meaningful weight loss alongside other lifestyle changes.

Did Post Malone have weight-loss surgery? No public statement suggests bariatric surgery. He has consistently attributed the change to dietary modification.

Did Post Malone use Ozempic or Wegovy? He has denied it. The denial has been stable across interviews and has not been contradicted by emergent evidence.

Should I trust a celebrity denial of Ozempic use? Treat denials as the public record while acknowledging that celebrities have reasons to deny use even when accurate. The base-rate question matters: blanket skepticism produces more false positives than accurate detection.

Does Post Malone's weight-loss pattern match GLP-1 use? Not particularly well. His public discussion has emphasized appetite control through dietary discipline, soda cessation, and a stated motivation tied to fatherhood. He has not described reduced food noise, nausea, or other markers commonly mentioned by patients on GLP-1 medications.

What did Post Malone weigh before and after? Specific weights have not been disclosed. The 60-pound delta is his stated figure, with starting and ending points not publicly given.

Is Post Malone's approach realistic for the average person? The approach (eliminate excess calories from a specific source, sustain dietary improvement over months, anchor the change to a meaningful motivation) is realistic but not automatic. Behavioral change is hard, and his case fits a profile (clear baseline excess, strong motivation, supportive environment) that not everyone shares.

Should I try cutting soda to lose weight like Post Malone? If you consume significant full-sugar soda, eliminating it is a low-cost intervention with low risk. Whether it will produce results comparable to Post Malone's depends on your baseline intake, your overall caloric balance, and other lifestyle factors. A clinician or registered dietitian can help calibrate expectations.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Rubino D et al. STEP 4: Semaglutide Maintenance of Weight Loss. JAMA. 2021.
4. Aronne LJ et al. SURMOUNT-4: Tirzepatide Maintenance Trial. JAMA. 2024.
5. Lincoff AM et al. SELECT: Cardiovascular Outcomes with Semaglutide. New England Journal of Medicine. 2023.
6. Malik VS et al. Sugar-Sweetened Beverages and Weight Gain: A Systematic Review and Meta-Analysis. American Journal of Clinical Nutrition. 2013.
7. Mozaffarian D et al. Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men. New England Journal of Medicine. 2011.
8. American Heart Association. Scientific Statement on Added Sugars and Cardiovascular Risk. 2021.
9. Endocrine Society. Clinical Practice Guideline: Pharmacological Management of Obesity. 2022.
10. American Association of Clinical Endocrinologists. Pharmacotherapy Guidance for Obesity. 2024.
11. FDA Drug Approvals Database. Semaglutide and Tirzepatide labeling.
12. FDA. Drug Compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Footer disclaimers

FormBlends Platform Notice. FormBlends is a digital health platform connecting patients with independent licensed clinicians and U.S.-based compounding pharmacies. We do not prescribe, manufacture, or dispense medication ourselves; clinical judgments rest with the prescribing clinician.

Compounded Product Notice. Compounded semaglutide and compounded tirzepatide have not been approved by the FDA. They are prepared by state-licensed 503A compounding pharmacies in response to a prescription written for a specific individual. They have not been reviewed by the FDA and are not interchangeable with brand products including Ozempic, Wegovy, Mounjaro, or Zepbound.

Outcomes and Variation Notice. Outcomes referenced in this article reflect averages reported in published clinical trials or self-reported figures from public statements. They are not predictions for any individual patient. Real-world results vary based on adherence, baseline weight, comorbidities, and many other factors.

Trademark and Affiliation Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Coca-Cola is a registered trademark of The Coca-Cola Company. Bud Light is a trademark of Anheuser-Busch. Post Malone's name and brand are his own. FormBlends has no affiliation with, endorsement from, or partnership with Post Malone, The Coca-Cola Company, Anheuser-Busch, Novo Nordisk, or Eli Lilly.